Khalid Islam - Aug 9, 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: Executive Chairman, Director
Signature: /s/ Khalid Islam
Stock symbol: GANX
Transactions as of: Aug 9, 2024
Transactions value $: $49,940
Form type: 4
Date filed: 8/12/2024, 05:23 PM
Previous filing: Jun 26, 2024
Next filing: Aug 19, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Purchase	$49.9K	+50K		$1.00	50K	Aug 9, 2024	Direct	F2
holding	GANX	Common Stock						881K	Aug 9, 2024	See footnote	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is the ultimate shareholder of 1 MM & 1 PP AG, which is the direct beneficial owner of the securities.
F2	The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Content

The Reporting Person is the ultimate shareholder of 1 MM & 1 PP AG, which is the direct beneficial owner of the securities.

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.